🇺🇸 FDA
Pipeline program

Dapagliflozin

D1690L00067

Approved small_molecule completed

Quick answer

Dapagliflozin for Diabetes Mellitus, Type 2 is a Approved program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Diabetes Mellitus, Type 2
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials